Barrett esophagus. Bible class Inselspital

Similar documents
Barrett s Esophagus: Old Dog, New Tricks

Barrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI

Management of Barrett s Esophagus. Case Presentation

ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus

New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus

History. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management

Barrett s esophagus. Barrett s neoplasia treatment trends

Endoscopic Management of Barrett s Esophagus

MANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018

Oesophagus and Stomach update dysplasia and early cancer

AGA SECTION. Gastroenterology 2016;150:

In 1998, the American College of Gastroenterology issued ALIMENTARY TRACT

Management of Barrett s: From Imaging to Resection

Screening of Barrett: Is it cost-effective? Is there a high-risk population? T Ponchon Ed. Herriot Hospital Lyon, France

Learning Objectives:

Present Day Management of Barrett s Esophagus

Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus

Ablation for Barrett s Esophagus: Burn or Freeze

Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia

Joel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery

Citation for published version (APA): Phoa, K. Y. N. (2014). Endoscopic management of Barrett s esophagus with dysplasia

Changes to the diagnosis and management of Barrett s Oesophagus

Accepted Manuscript. CGH Editorial: Sound the Alarm for Barrett s Screening! Tarek Sawas, M.D., M.P.H., David A. Katzka, M.D

Barrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD?

Barrett s Esophagus: Ablate Everyone?

ESD for EGC with undifferentiated histology

How to stage early BE cancer - EUS or endoscopic removal?

Barrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions

Everything Esophagus: Barrett s Esophagus. Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina

Definition of GERD American College of Gastroenterology

Current Management of Low-Grade Dysplasia in Barrett Esophagus

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Surgical Problems in Proximal GI Cancer Management Cardia Tumours Question #1: What are cardia tumours?

Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care

Burning Issues in the Esophagus

Chapter 12: Training in Pathology. DDSEP Chapter 13: Question 19

National Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia

The Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin

Chapter 2 Complications of Gastroesophageal Reflux Disease

Esophageal cancer: Biology, natural history, staging and therapeutic options

What s New in the Management of Esophageal Disease

Frequency of Barrett Esophagus in Patients with Symptoms of Gastroesophageal Reflux Disease

Volumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment Barrett s esophagus

Original article INTRODUCTION

Quiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False

Henry Moon was one of the giants in academic pathology during my early years.

How to remove BE cancer: EMR or ESD? Expected outcome

Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy

Evaluating Treatments of Barrett s Esophagus That Shows High-Grade Dysplasia

RFA and Cyrotherapy for Esophageal Disease

Current status of gastric ESD in Korea. Jun Haeng Lee. Department of Medicine Sungkyunkwanuniversity School of Medicie, Seoul, Korea

Greater Manchester & Cheshire Guidelines for Pathology Reporting of Oesophageal and Gastric Malignancy

Barrett s Esophagus: Are We Making any Progress?

ESOPHAGEAL CANCER. Epidemiology 3/22/2017. Esophageal Carcinoma: subtypes. Esophageal Adenocarcinoma (EAC) Epidemiology.

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Faculty Disclosure. Objectives. State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) 24/11/2014

Is Radiofrequency Ablation Effective In Treating Barrett s Esophagus Patients with High-Grade Dysplasia?

ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

Disclosures. Gastroesophageal Reflux Disease. Gastroesophageal Reflux Disease

Adenocarcinoma of the distal esophagus is a recognized

Gastrointestinal pathology 2018 lecture 2. Dr Heyam Awad FRCPath

Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia?

Index. Note: Page numbers of article titles are in boldface type.

SAM PROVIDER TOOLKIT

SAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST QUESTIONS. Ver. #

Barrett's Esophagus: Sorting Out the Controversy

Disclosures. Gastric Intestinal Metaplasia and Early Gastric Cancer: Screening, Surveillance, and Endoscopic Therapy. ASGE Guidelines.

Barrett Esophagus - RadioFrequency Ablation (BE-RFA) - Project manual + FAQ

How to characterize dysplastic lesions in IBD?

From reflux to esophageal cancer. Josh Boys, MD TCV 2 nd year indentured servant

Endoscopic Radiofrequency Ablation or Cryoablation for Barrett`s Esophagus. Original Policy Date

Hiatal Hernias and Barrett s esophagus. Dr Sajida Ahad Mercy General Surgery

Table 2.9. Case control studies of helicobacter pylori infection and oesophageal adenocarcinoma

Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus

Oesophageal Disorders

THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 97, No. 1, by Am. Coll. of Gastroenterology ISSN /02/$22.00

Targeting care in Barrett s oesophagus

The presence of intestinal-type goblet cells (ITGCs) in

Barrett s Esophagus: State of the Art Management

Current Management: Role of Radiofrequency Ablation

Disclosures. Heartburn and Barrett s Esophagus. Heartburn and Barrett s Esophagus. GERD is common in the U.S. None

Barrett s Oesophagus Information Leaflet THE DIGESTIVE SYSTEM. gutscharity.org.

Minimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006

Vital staining and Barrett s esophagus

When to Refer for OGD and the Work Up of Upper GI Malignancies

Large polyps: EMR, ESD, TEM and segmental resection. Terry Phang 2017 SON fall update

Editorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading?

Endoscopic management of Barrett s esophagus:european Society of Gastrointestinal Endoscopy (ESGE) Position Statement

Barrett s Esophagus: State of the Art. Food Getting Stuck

ESOPHAGEAL CANCER AND GERD. Prof Salman Guraya FRCS, Masters MedEd

Sixteen-year follow-up of Barrett s esophagus, endoscopically treated with argon plasma coagulation

Health technology Endoscopic surveillance of Barrett's oesophagus to detect malignancy in an early and curable stage.

Gregory G. Ginsberg, M.D.

CLINICAL EFFECTIVENESS

Case Scenario year-old white male presented to personal physician with dyspepsia with reflux.

Barrett s esophagus: lessons from recent clinical trials

Barrett s Esophagus. lining of the lower esophagus that bears his name (i.e., Barrett's esophagus). We now

GI update. Common conditions and concerns my patients frequently asked about

ORIGINAL ARTICLE. Adenocarcinoma of the Esophagus With and Without Barrett Mucosa

Transcription:

Barrett esophagus Bible class Inselspital 2015.08.10

Guidelines

Definition? BSG: ACG:

Definition? BSG: ACG:

What are the arguments for and against IM as prerequisite for the Dg?

What are the arguments for and against IM as prerequisite for the Dg? - Intestinal metaplasia is biologically more unstable Bhat S et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.j Natl Cancer Inst 2011. - Possible sampling error (false negativ Bx) Harrison R et al. Detection of intestinal metaplasia i Barrett s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007 - Evolution of IM over the time Gatenby PA et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol 2008

What are the arguments for and against IM as prerequisite for the Dg? - < 50 of endoscopically resected OAC have IM Takubo K et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 2009.

What are the arguments for and against IM as prerequisite for the Dg? - < 50 of endoscopically resected OAC have IM Takubo K et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 2009. Is IM of the cardia of concern?

What are the arguments for and against IM as prerequisite for the Dg? - < 50 of endoscopically resected OAC have IM Takubo K et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 2009. Is IM of the cardia of concern? - No, 20% of people harbour IM Zaninotto G et al. Prevalence of intestinal metaplasia in the distal oesophagus, oesophagogastric junction and gastric cardia in symptomatic patients in north-east Italy. Dig Liver Dis 2001.

How is the distal esophageal and endoscopically defined?

How is the distal esophageal and endoscopically defined?

How is the distal esophageal and endoscopically defined? Is this a potential barrett esophagus?

How is the distal esophageal and endoscopically defined? Is this a potential barrett esophagus? No!

What describes the Prague Classification?

What describes the Prague Classification?

What should be further recorded?

What should be further recorded?

Biopsy protocol and importang aspects of sampling?

Biopsy protocol and importang aspects of sampling? - Targeted biopsies from visible lesions - 4 Quadrant biopsies every 2 cm - Optimize visualisation (Inspection of the OGJ by inversion if possible, careful flushing, acetic acid, starting distal and basal, inspection time!)

Screening/surveillance «Optimal» disease for a screening?

Screening/surveillance - «Optimal» disease for a screening? Disease with a high morbidity/mortality A early diagnosis leads to improved survival High prevalence of the disease in a certain population - High positive and negative predictive values of the test - Cost effective and well tolerated test/treatment

Screening Whats the prevalence of BE?

Screening Whats the prevalence of BE? -.5% 5% if GERD)

Screening Whats the prevalence of BE? -.5% 5% if GERD) What are the risk factors of BE?

Screening - Whats the prevalence of BE?.5% 5% if GERD) What are the risk factors of BE? Male gender, caucasian ethnicity Older age History of GERD Possible cigarette smoking Family history Abdominal adiposity

Is screening recommended?

Is screening recommended?

Surveillance Is there evidence I for surveillance?

Surveillance Is there evidence I for surveillance? - No, BOSS trial avaited

What are the most important arguments for the surveillance?

What are the most important arguments for the surveillance? - OAC has a very poor overall 5 year survival < 20% - OAC detected by screening have an earlier stage and better survival rate

What are the most important arguments for the surveillance? - OAC has a very poor overall 5 year survival < 20% - OAC detected by screening have an erlier stage and better survival rate Usefullness of surveillance proved?

What are the most important arguments for the surveillance? - OAC has a very poor overall 5 year survival < 20% - OAC detected by screening have an erlier stage and better survival rate Usefullness of surveillance proved? - No!

Why?

Why? - Lenght time bias:

- Lead time bias:

Is surveillance recommended?

Is surveillance recommended?

What s the incidence of OAC in BE?

What s the incidence of OAC in BE? - 0.16%/year Bhat S et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.j Natl Cancer Inst 2011. - 0.12%/year Hvid-Jensen F et al. Incidence of adenocarcinoma among patients with Barrett s esophagus. N Engl J Med 2011. - 0.33%/year Desai TK et al. Th e incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012

What are the risk factors for malignant progression?

What are the risk factors for malignant progression? - Advancing age - Male gender - S oki g HR! - Length of Barrett esophagus - Ulcers, strictures and nodules! - Lack of PPI, NSAID/ASS, Statins

What are the risk factors for malignant progression? - Advancing age - Male gender - S oki g HR! - Length of Barrett esophagus - Ulcers, strictures and nodules! Metaanalysis of - Lack of PPI, NSAID/ASS, Statins cohort studies

Is chemoprevention indicated?

Is chemoprevention indicated? - AspECT trial awaited

Is chemoprevention indicated? - AspECT trial awaited Is fundoplicatio indicated?

Is chemoprevention indicated? - AspECT trial awaited Is fundoplicatio indicated?

What s the likelyhood to die from an Barrett unrelated cause in patients without dysplasia?

What s the likelyhood to die from an Barrett unrelated cause in patients without dysplasia? - > 90% Incarbone R et al. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002.

What s the likelyhood to die from an Barrett unrelated cause in patients without dysplasia? - > 90% Incarbone R et al. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002. What s the risk of progression of dysplasia?

What s the likelyhood to die from an Barrett unrelated cause in patients without dysplasia? - > 90% Incarbone R et al. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002. What s the risk of progression of dysplasia?

How is the surveillance proposed?

How is the surveillance proposed? ECOG score 0-2 (self care possible)

How is low grade dysplasia defined?

How is low grade dysplasia defined?

How is high grade dysplasia defined?

How is high grade dysplasia defined?

Is the interobserver agreement good for dysplasia?

Is the interobserver agreement good for dysplasia? - No, especially for low grad dysplasia

Is the interobserver agreement good for dysplasia? - No, especially for low grad dysplasia How it could be improved? - Immunostaining with p53

Is the interobserver agreement good for dysplasia? - No, especially for low grad dysplasia How it could be improved?

Is the interobserver agreement good for dysplasia? - No, especially for low grad dysplasia How it could be improved? - Immunostaining with p53

How should we manage dysplasia?

How should we manage dysplasia?

What about the SURF trial?

What about the SURF trial?

What about the SURF trial?

What are the therapeutic options with HGD?

What are the therapeutic options with HGD?

Risk of lymph node mestasis in T1?

Risk of lymph node mestasis in T1? - T1a: 0-10% - T1b SM1: conflicting data, if R0L0 an poor surgical candidate => endoscopic resection - T1b SM2-3: Risk up to 46% => Surgery

What should be done after curative endoscopic resection?

What should be done after curative endoscopic resection? - Eradication of BE (>80 have remaining dysplasia, 20% metachronous lesions in 2 years

What should be done after curative endoscopic resection? - Eradication of BE (>80 have remaining dysplasia, 20% metachronous lesions in 2 years) Is (PET)-CT indicated if early esophageal cancer is supposed?

What should be done after curative endoscopic resection? - Eradication of BE (>80 have remaining dysplasia, 20% metachronous lesions in 2 years) Is (PET)-CT indicated if early esophageal cancer is supposed? - No

What should be done after curative endoscopic resection? - Eradication of BE (>80 have remaining dysplasia, 20% metachronous lesions in 2 years) Is (PET)-CT indicated if early esophageal cancer is supposed? - No What about EUS?

What should be done after curative endoscopic resection? - Eradication of BE (>80 have remaining dysplasia, 20% metachronous lesions in 2 years) Is (PET)-CT indicated if early esophageal cancer is supposed? - No What about EUS? - Can be done, but frequent over- (15 25%) and understaging (4 12%) of T1 vrs T2

How should we follow up the patients?

How should we follow up the patients? - Every 3 month for 1 year, than yearly - Biopsies of the prior extend of BE (burried dysplasia!)

How should we follow up the patients? - Every 3 month for 1 year, than yearly - Biopsies of the prior extend of BE (burried dysplasia!)